marijuana stocks

GB Sciences and NRC Research Institute Apply Crowdsourcing and Big Data Analytics to the Discovery and Validation of Cannabis-Based Therapies

LAS VEGAS, Nov. 10, 2014 (GLOBE NEWSWIRE) — GrowBLOX Sciences, Inc., “GB Sciences” (GBLX), a company that merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize safe and consistent medicinal cannabis, and NRC Research Institute (“NRC”) announce the joint development of a crowdsourcing application to discover cannabis-based therapeutic combinations that are effective in the treatment of serious disorders. The app uses real-time patient feedback, impairment testing, and biometric measurements to assess the efficacy of therapeutic products made with prescreened cannabis strains.

“Patients need help in finding the correct strain of Cannabis to treat their medical conditions,” said Andrea L. Small-Howard, PhD, MBA, Chief Science Officer of GB Sciences. “Because GB Sciences has a suite of proprietary GrowBLOXTM technologies designed to produce consistent, medical-grade cannabis products with known cannabinoid-terpene profiles, we will soon be able to correlate patient symptoms and pathology with the right ‘cocktails’ of active ingredients for the first time. Any trial that has tested cannabis-based products without controlling the levels of active ingredients in the plant strains cannot accurately gauge their medicinal value. Once cannabis cocktail mixtures are validated as effective, they will become the source of our novel cannabinoid therapies. The app is our Drug Discovery Engine.”

The research firms anticipate thousands of patients will download and use their free electronic Patient Reported Outcomes (GBLX-PRO) app to report and track their experience with different pre-screened strains of medicinal cannabis that are provisionally assigned to seven different treatment categories. In addition, the anonymously collected patient data will contribute to cannabis research and enable GB Sciences to demonstrate which of its pre-screened strains are effective in treating medical conditions such as Parkinson’s disease, epilepsy, anxiety, insomnia, pain and metabolic disorders. The GBLX-PRO app will aid in creating personalized treatments for patients with unmet clinical needs.

“This exciting strategic partnership with GB Sciences provides for the successful development of their product pipeline and will help innovate measurements for high-priority therapeutic indications in the cannabis drug development process,” said Tony Ortiz, Ph.D., CEO of NRC Research Institute.

Collection and analysis of the two sets of data—cannabis strain potency and patient response to therapy—will enable GB Sciences to monitor and validate dosage levels and their effectiveness in treating specific medical conditions. The GBLX-PRO app will allow for three levels of participation: 1) self-reporting of clinical results using validated surveys; 2) participation in objective impairment testing; and 3) the collection of biometric data voluntarily submitted by participating patients via smartphone accessories. The GBLX-PRO app collects and combines rich objective and subjective patient feedback with lot-specific growth data that GB Sciences collects from its cannabis-growing operations.

“Crowdsourcing efficacy data is now possible because 23 states and Washington, D.C. allow patients to use cannabis,” said Craig Ellins, CEO of GrowBLOX Sciences. “When collected and properly analyzed in our big data program, the patient information will provide a roadmap pointing which direction we need to head to treat specific illnesses. For the first time, we are going to have the ability to validate our strains for specific disorders.”

To learn more about GB Sciences, Inc., go to

About GrowBLOX Sciences, Inc.

GB Sciences is a biopharmaceutical research and development company that merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize our safe and consistent medicinal cannabis. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

About NRC Research Institute

NRC Research is a Clinical Research and Development company with a focus on Contract Research Organization services to the pharmaceuticals and biotechnology companies. NRC Research Institute has worked with numerous globally recognized pharmaceutical and biotechnology companies on the development of experimental medications for FDA approval and other clinical development services.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media and Investor Relations Contact:
Stephen Hart
Hayden IR

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$CBIS Signs Gary Blick, MD and Proceeds With CS-TATI-1 for HIV

Cannabis Science Signs Gary Blick, MD and Proceeds With CS-TATI-1 for HIV…

$EAPH Releases December Vaporizer Sales

Easton Pharmaceuticals Releases December Vaporizer Sales, Highlighting a 62% Month Over Month…

Digipath, Inc. (DIGP) Announces Revenue Increase of Almost 18% for the Fourth Quarter of Fiscal Year 2022

Digipath, Inc. Announces Revenue Increase of Almost 18% for the Fourth Quarter…

$PZOO Licensee Harris Lee Colorado Has Best Month Since September 2015

Pazoo Licensee Harris Lee Colorado Has Best Month Since September 2015 Pazoo,…